hVIVO (LON:HVO) Trading 7.1% Higher – What’s Next?

hVIVO plc (LON:HVO)’s stock price shot up 7.1% during mid-day trading on Thursday . The stock traded as high as GBX 13.50 ($0.18) and last traded at GBX 13.50 ($0.18). 1,485,919 shares changed hands during trading, a decline of 55% from the average session volume of 3,282,514 shares. The stock had previously closed at GBX 12.60 ($0.16).

hVIVO Price Performance

The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The company has a market cap of £97.51 million, a PE ratio of 5.68 and a beta of 0.97. The stock has a fifty day moving average price of GBX 16.97 and a 200-day moving average price of GBX 21.58.

Insiders Place Their Bets

In other news, insider Yamin Mo’ Khan sold 3,062,246 shares of the company’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.22), for a total value of £520,581.82 ($675,992.49). Corporate insiders own 14.03% of the company’s stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.